Ilaris (canakinumab) for injection 180mg sterile powder

How It Works

Ilaris (canakinumab) is a monoclonal antibody that targets interleukin-1 beta (IL-1β), a pro-inflammatory cytokine involved in various inflammatory diseases. By binding to IL-1β, canakinumab prevents it from interacting with its receptors, thereby inhibiting the inflammatory response. This mechanism is particularly beneficial in conditions where IL-1β plays a key role in driving inflammation, helping to reduce symptoms and prevent flare-ups.

List of Side Effects

• Infections (e.g., upper respiratory tract infections)
• Injection site reactions
• Abdominal pain
• Headache
• Diarrhea
• Cold symptoms (nasopharyngitis)
• Flu-like symptoms
• Dizziness
• Nausea
• Back pain

List of Indications

• Periodic fever syndromes including:
  • Cryopyrin-Associated Periodic Syndromes (CAPS) in adults and children aged 4 years and older, including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)
  • Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older
  • Adult-Onset Still’s Disease (AOSD)
• Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)
• Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
• Familial Mediterranean Fever (FMF)

List of Contraindications

• Known hypersensitivity to canakinumab or any of its excipients
• Active severe infections

Price in Different Countries

Top 5 Global Brands

1. Ilaris (Canakinumab) – Novartis
2. Kineret (Anakinra) – Swedish Orphan Biovitrum
3. Actemra (Tocilizumab) – Roche
4. Humira (Adalimumab) – AbbVie
5. Enbrel (Etanercept) – Amgen